COPENHAGEN (Reuters) – The Danish pharmaceutical group Novo Nordisk announced on Monday the upcoming acquisition of Cardior Pharmaceuticals for an amount estimated at 1.03 billion euros with a view to strengthening its division against cardiovascular diseases.
The Danish company, which specializes in therapies against diabetes and obesity, has become one of the most profitable companies in the world thanks to its drug Wegovy, which provides notable results in the management of overweight and obesity.
“By welcoming Cardior to Novo Nordisk, we will strengthen our projects in the field of cardiovascular diseases, where we already have ongoing programs at all stages of clinical development,” Novo Nordisk said in a statement.
The deal includes Cardior’s lead compound, CDR132L, currently in phase 2 clinical development for the treatment of heart failure, Novo said.
The compound is designed to halt and partially reverse the progression of the disease in people with heart failure, which could lead to lasting improvement in heart function, the company added.
The transaction is expected to be finalized during the second quarter of 2024.
(Report by Louise Breusch Rasmussen, French version by Diana Mandiá)
Copyright © 2024 Thomson Reuters